Felbamate

CHEMBL1094 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

238.2 g/mol

LogP

0.6

Phase

4

This anticonvulsant works through multiple mechanisms including blocking NMDA receptors and sodium channels to control seizures, particularly in patients with severe, treatment-resistant epilepsy such as Lennox-Gastaut syndrome. It is reserved for severe cases due to the risk of serious side effects.

الوزن الجزيئي

238,2400 g/mol

LogP

0,60

TPSA

105,00 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Epilepsy Bipolar Disorder

آلية العمل

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

NC(=O)OCC(COC(N)=O)c1ccccc1

InChI

InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)

Molecular Formula

C11H14N2O4

HBD / HBA

2 / 4

الروابط القابلة للدوران

7

الذرات الثقيلة

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This anticonvulsant works through multiple mechanisms including blocking NMDA receptors and sodium channels to control seizures, particularly in patients with severe, treatment-resistant epilepsy such as Lennox-Gastaut syndrome. It is reserved for severe cases due to the risk of serious side effects.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Felbamate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1094. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3331. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Felbamate على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C11H14N2O4
المرادفات: 1

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.